Your Search Returned 63 tagged news reports
Designed to determine efficacy level of melflufen in combination with dexamethasone for late stage, relapsing or relapsing/refractory patients, the open-label trial is being conducted across four centers in the Netherlands, Italy, Denmark and Sweden
In a setback to expanding the market for its flagship drug, Celgene has ended a Phase III trial of Revlimid, which was being tested in elderly patients with a type of blood cancer known as B-cell chronic lymphocytic leukemia, because there were a
Celgene Corp. moved higher in premarket trade Thursday, helped by positive results in a late-stage study of its cancer drug Revlimid...Early Thursday, the company said patients newly diagnosed with multiple myeloma who took Revlimid combined with
The Record A new drug has been approved to battle mantle cell lymphoma, an aggressive cancer often fatal because of its resistance to treatment, after a study led by a Hackensack University Medical Center physician showed it can stop the progression
It had hit all-time highs in nine of the last 10 sessions and, on Thursday, the index did something unconventional: It took a step back. Perhaps it was warranted, as new housing starts slipped big-time in April (more than 16%), and recent industrial
Health Canada is warning people taking a thalidomide drug that users may be at risk of developing blood clots in their arteries. The warning was issued about the drug Thalomid, which is used in people aged 65 and older as a treatment for a blood
Hot Biotech Stocks to Buy Now Which biotech stocks should investors take a hard look at buying now? Health care analyst Max Macaluso sat down with Fool.com contributor Keith Speights recently to find out which stocks he likes in the biotech sector.
may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic compounds. The health care leader was one of the few to show growth in both worldwide
Pomalyst, the third drug in a class of immunomodulatory agents including lenalidomide and thalidomide, adjusts immune system of the body to destroy and inhibit the growth of cancerous cells. The drug is indicated for patients in whom the disease
Patients must have received at least two prior therapies including Revlimid and Velcade and show progression of the disease. What it means The immediate impact of the FDA decision is that Pomalyst will hit the market over the next few weeks. Celgene'